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URAT1 (slc22a12) was identiﬁed as the transporter responsible for renal reabsorption of the medically
important compound, uric acid. However, subsequent studies have indicated that other transporters
make contributions to this process, and that URAT1 transports other organic anions besides urate (in-
cluding several in common with the closely related multi-speciﬁc renal organic anion transporters, OAT1
(slc22a6) and OAT3 (slc22a8)). These ﬁndings raise the possibility that urate transport is not the sole
physiological function of URAT1. We previously characterized mice null for the murine ortholog of URAT1
(mURAT1; previously cloned as RST), ﬁnding a relatively modest decrement in urate reabsorptive ca-
pacity. Nevertheless, there were shifts in the plasma and urinary concentrations of multiple small mo-
lecules, suggesting signiﬁcant metabolic changes in the knockouts. Although these molecules remain
unidentiﬁed, here we have computationally delineated the biochemical networks consistent with tran-
scriptomic data from the null mice. These analyses suggest alterations in the handling of not only urate
but also other putative URAT1 substrates comprising intermediates in nucleotide, carbohydrate, and
steroid metabolism. Moreover, the analyses indicate changes in multiple other pathways, including those
relating to the metabolism of glycosaminoglycans, methionine, and coenzyme A, possibly reﬂecting
downstream effects of URAT1 loss. Taken together with the available substrate and metabolomic data for
the other OATs, our ﬁndings suggest that the transport and biochemical functions of URAT1 overlap those
of OAT1 and OAT3, and could contribute to our understanding of the relationship between uric acid and
the various metabolic disorders to which it has been linked.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The renal transporter, URAT1 [1], encoded by the human ortholog
of the previously identiﬁed mouse gene, RST[2], was identiﬁed as the
principal agent of proximal tubular reabsorption of uric acid, a
medically important metabolite linked to renal and cardiovascular
dysfunction as well as gout [3–5]. However, recent biochemical as
well as genetic evidence indicates that several other transporters,
including, prominently, GLUT9 [6–9], as well as ABCG2, NPT1, NPT4,
and MRP4, make major contributions to the renal handling of urate
(reviewed in [10–12]). Moreover, URAT1 transports not only urate,
but also multiple other compounds (including endogenousB.V. This is an open access article u
coefﬁcient of variationmetabolites such as acetoacetate, lactate, and orotate), a number of
which are also substrates of the closely related multispeciﬁc renal
organic anion transporters, OAT1 and OAT3 [13,14]; additionally,
URAT1, like OAT1 and OAT3, is an exchanger that can mediate the
bidirectional transport of its substrates [1,15]. Collectively, these
ﬁndings raise the possibility that URAT1 might have signiﬁcant
functions distinct from urate reabsorption.
RST was established as the murine homolog of URAT1, mURAT1,
on the basis of sequence homology [14,16] and functional simi-
larity [15]. We characterized mice null for mURAT1, ﬁnding, con-
sisted with the studies noted above, a relatively modest loss of
urate reabsorptive capacity [17]. We subsequently performed
metabolomic analyses of plasma and urine in these knockouts.
Targeted measurements of the most abundant small organic an-
ions did not reveal any differences between wild-type and mUR-
AT1 knockout mice. However, global (untargeted) metabolomic
measurements revealed signiﬁcant changes in the plasma andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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gesting an altered metabolite proﬁle in the knockouts [17].
Although the latter molecules have not yet been identiﬁed,
here we have computationally deﬁned the biochemical networks
consistent with transcriptomic data from the null mice.. Compu-
tational reconstruction of metabolic networks based on the con-
straints imposed by extant patterns of gene expression have been
demonstrated to have predictive value in a variety of model sys-
tems (reviewed in [18]). We previously implemented such ap-
proaches to identify metabolic networks associated with OAT1 and
its near paralog, OAT3, via analyses of the corresponding knockout
mice. These studies implicated OAT function in multiple metabolic
pathways, including the pentose phosphate shunt, the Krebs cycle,
and the polyamine pathway (OAT1; [18]), xenobiotic hydroxylation
and glucuronidation, the metabolism of ﬂavonoids and other
products of the gut microbiome, and prostaglandin, cyclic nu-
cleotide, and glycosaminoglycan metabolism (OAT3; [19]), ﬁndings
generally consistent with the transport and metabolomic data for
OAT1 and OAT3. In order to better understand the role of URAT1
beyond urate transport, we have now performed analogous global
metabolic reconstructions based on transcriptomic data from
mURAT1 knockout mice. Our ﬁndings suggest the involvement of
mURAT1 in metabolic processes overlapping those associated with
OAT1 and OAT3, including pathways relating to carbohydrate,
nucleotide, glycosaminoglycan, and coenzyme A metabolism,
among others.2. Materials and METHODS
2.1. Gene expression determinations
The generation and breeding of mURAT1 knockout mice and
the collection of microarray data on renal gene expression in
mUrat1 and the corresponding wild-type mice was previously
reported (Eralyn et al., 2008). In brief, RST-null mice were gener-
ated by homologous recombination and then back-crossed to
C57BL/6 J mice for seven generations to yield the progenitors from
which experimental animals (wild-type as well as knockout) were
descended. Quantitative PCR analysis of the expression of mOat1,
mOat3, and mUrat1 was performed as follows: RNA from wild-
type and mUrat1 knockout kidneys (n¼3 per group) was puriﬁed
on RNeasy columns (Qiagen, Valencia, CA), reverse transcribed
using SuperScript III (Invitrogen, Carlsbad, CA), and the resulting
cDNA samples was subjected to duplicate real-time PCR reactions
at the University of California, San Diego/Veterans Affairs Medical
Center’s (UCSD/VAMC) Center for AIDS Research Genomics Core
laboratory. Gene expression values were normalized to that of
GAPDH in the corresponding cDNA samples. Gene-speciﬁc primer
sequences (5′ to 3′) were as follows [please note that the ﬁrst 18
bases (ACT GAA CCT GAC CGT ACA) on each forward primer cor-
respond to the “Z sequence” that is complementary to the “uni-
primer” used in the Ampliﬂuor system]: mOat1 (mSlc22a6), ACT
GAA CCT GAC CGT ACA GCA TGA CTG CCG AGT TCT ACC (forward)
and CAG CGC CGA AGA TGA AGA G (reverse); mOat3 (mSlc22a8),
ACT GAA CCT GAC CGT ACA GCA GCC CTT CAT CCC TAA TG (for-
ward) and CCT CCC AGT AGA GTC ATG GTC AC (reverse); and
mUrat1 (mSlc22a12), ACT GAA CCT GAC CGT ACA CCA TGC TAG
GGC CTT TGG TA (forward) and GCA TCC AGG AGC CAT AGA CAC
(reverse).
2.2. Determination of enriched functions in differentially expressed
or variable genes
Renal gene expression patterns in wild-type and mURAT1
knockout mice as determined by microarray analysis werecompared using VAMPIRE (http://genome.ucsd.edu/microarray;
accessed February 11th, 2015), which takes variability differences
between genotypes (which can be substantial (Eraly, 2014)) into
account in determining the statistical signiﬁcance of any gene
expression differences (Hsiao et al., 2005, Hsiao et al., 2004). Dif-
ferentially expressed genes were identiﬁed as those meeting the
statistical signiﬁcance threshold of po0.05 following Bonferroni
correction for multiple comparisons. Functional annotations en-
riched among differentially expressed genes were determined
using the AmiGO tool (http://amigo1.geneontology.org/; accessed
February 11th, 2015), with the p value threshold set at 10-5 and
the background set drawn from the Mouse Genome Informatics
database (http://informatics.jax.org; accessed February 11th,
2015).
There appear to be, generally, highly signiﬁcant differences
between knockout and wild-type mice in mean gene expression
variability (Eraly, 2014). Speciﬁcally, in each of multiple microarray
comparisons of gene expression in wild-type and diverse knockout
mice, the mean log coefﬁcient of variation (CV) ratio (the mean, for
the various measured genes, of the logs of the ratios of CV of ex-
pression in knockout to CV in wild-type – equivalent to calculating
the geometric mean of the CV ratio; please see (Eraly, 2014) for the
rationale for this procedure) was found to typically deviate highly
signiﬁcantly from zero, the expected value if there were no dif-
ferences between knockout and wild-type mice in gene expression
variability. Moreover, the distribution of the log CV ratios was
found to be approximately Gaussian. As such, in the current study,
we considered genes to be differentially variable if they fell within
the top or bottom 1% of the expected distribution of the log CV
ratios; i.e., had variability differences signiﬁcantly greater or lesser
than the mean variability difference between mURAT1 knockout
and wild-type mice. Functional annotations enriched among these
differentially variable genes were also determined using AmiGO,
as described above for differentially expressed genes.
2.3. Gene expression-based metabolic network reconstruction
Microarray gene expression detection p-values were mapped to
their corresponding reactions in the genome scale computational
metabolic reconstruction, iMM1415 ((Sigurdsson et al., 2010), the
murine version of the previously developed human metabolic
reconstruction, Recon1 (Duarte et al., 2007)), based on gene-pro-
tein-reaction associations (Thiele and Palsson, 2010). The Gene
Inactivity Moderated by Metabolism and Expression algorithm
(GIMME; (Becker and Palsson, 2008)) provides summations of the
most probable network ﬂux states consistent with actively ex-
pressed genes and capable of achieving deﬁned objective func-
tions, thereby permitting quantiﬁcation of the consistency of gene
expression data with various metabolic objectives. In this study
biomass was deﬁned as the objective function, and the GIMME
algorithm was used to generate the metabolic reconstructions
most consistent with the wild-type and mURAT1 knockout mouse
gene expression data, as previously described (Wu et al., 2013).
Renal-speciﬁc uptake and secretion exchange constraints (as pre-
viously used to analyze blood pressure regulation (Chang et al.,
2010)) were used across all conditions, so that calculated differ-
ences were only a function of changes in gene expression proﬁles.
Each network reaction was then set as a required metabolic ob-
jective and the range of achievable ﬂux states, hereafter referred to
as ﬂux-span, was calculated, providing a measure of the likelihood
that the corresponding reaction was functional. Reactions having
ﬂux-span increased or decreased by two fold or greater in the
mURAT1 knockout relative to wild-type mice were determined,
and the proportions of these increased or decreased reactions
within each of the various metabolic sub-systems of iMM1415
were calculated.
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Fig. 1. Expression in mURAT1 knockout mouse kidneys of urate-regulating genes.
Gene expression levels in mURAT1 knockout (KO) and wild-type (WT) mice were
determined using microarrays (A) or quantitative PCR (B) and were normalized for
each gene to the mean level of expression in the WT. XDH, xanthine dehy-
drogenase; HGPRT, hypoxanthine guanine phosphoribosyl transferase; ADA, ade-
nosine deaminase; AMPD2, adenosine monophosphate deaminase 2; PNP, purine
nucleoside phosphorylase; UAT, urate transporter (galectin 9); MRP2, multidrug
resistance protein 2 (ATP-Binding Cassette Sub-Family C Member 2); MRP4, mul-
tidrug resistance protein 4 (ATP-Binding Cassette, Sub-Family C, Member 4);
ABCG2, ATP-binding cassette, sub-family G, member 2; NPT1, sodium-phosphate
transport protein 1 (slc17a1); NPT4, sodium-phosphate transport protein 4
(slc17a3); GLUT9, glucose transporter type 9 (slc2a9); OAT10, organic anion
transporter 10 (organic cation transporter like 3; slc22a13); OAT1, organic anion
transporter 1 (slc22a6); OAT3, organic anion transporter 3 (slc22a8). Data in Panel
A for XDH, HGPRT, ADA, AMPD2, PNP, UAT, MRP2, MRP4, NPT1, OAT1, OAT3, and
mURAT1 were reported previously [17]. Values represent mean7standard error.
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3.1. Functional annotations enriched among genes differentially ex-
pressed or variable in the mURAT1 knockout
We previously analyzed renal gene expression in mURAT1
knockout mice [17] focusing on genes known at that time to be
involved in urate metabolism and transport (including XDH, xan-
thine dehydrogenase; HGPRT, hypoxanthine guanine phosphor-
ibosyl transferase; ADA, adenosine deaminase; AMPD2, adenosine
monophosphate deaminase 2; PNP, purine nucleoside phosphor-
ylase; UAT, urate transporter (galectin 9); MRP2 & 4, multidrug
resistance proteins 2 & 4 (ATP-Binding Cassette Sub-Family C
Members 2 & 4); NPT1, sodium-phosphate transport protein 1
(slc17a1); OAT1 and OAT3), and found no substantial changes in
expression level. Examination of genes discovered since that prior
report to contribute to the renal handling of urate (including
glucose transporter type 9 (GLUT9; slc2a9), ATP-binding cassette,
sub-family G, member 2 (ABCG2), organic anion transporter 10
(OAT10; organic cation transporter like 3; slc22a13), and sodium-
phosphate transport protein 4 (NPT4; slc17a3); reviewed in [10–
12]) also did not reveal any signiﬁcant changes (Fig. 1A). (Note that
while organic anion transporter 4 (OAT4; slc22a11) has also been
implicated in renal urate transport, the murine genome appears to
lack an ortholog for this transporter ([20].) Moreover, there was no
signiﬁcant difference between wild-type and mURAT1 knockout
mice in the renal expression of the mURAT1-related transporters,
OAT1 and OAT3, as determined by quantitative PCR (Fig. 1B).
However, there was differential expression in mURAT1 knock-
out mouse kidneys of genes involved in various aspects of meta-
bolism, biosynthesis, cell cycle progression, apoptosis, and devel-
opment, among other processes (Supplementary Table 1, [17]).
Now that several studies have indicated that other proteins may be
equally if not more important uric acid transporters than URAT1,
and because a number of other URAT1 substrates have been
identiﬁed, we used, as a ﬁrst step, the gene ontology analysis tool
AmiGO (http://amigo1.geneontology.org/; accessed February 11th,
2015) to quantify the enrichment of general functional annotations
among the differentially expressed genes. We found the greatest
enrichment to be for the terms “cellular metabolic process”
(p¼3.261011) and “organic substance metabolic process”
(p¼1.03109) (Fig. 2A).
We also employed an additional method based on recent data
suggesting that differences in gene expression variability may
contribute to phenotype independent of any changes in average
gene expression (reviewed in [21]): we identiﬁed genes having
signiﬁcantly greater or lesser variability in the knockout compared
to the wild-type – essentially, those at the extremes of the dis-
tribution of the gene by gene ratios of the coefﬁcient of variation
(CV) in knockout to CV in wild-type (please see the Methods). As
with the differentially expressed genes, the differentially variable
genes encompassed diverse functions, including those related to
metabolism, cell cycle progression, growth factor signaling, and
transcriptional regulation (Supplementary Table 2). Again as with
the differentially expressed genes, though, the most signiﬁcant
enrichment was noted for the term “cellular metabolic process”
(p¼5.481012) (Fig. 2B), providing additional support for the
existence of metabolic alterations in the mURAT1 knockout, and
thus for a consequential role for mURAT1 in cellular metabolism.
3.2. Comparison of metabolic reconstructions derived from wild-type
and mURAT1 knockout renal transcriptomes
In order to obtain a ﬁner-grained picture of the metabolic
changes induced by deletion of mURAT1, we computationally de-
ﬁned the biochemical networks consistent with the transcriptomicdata from the knockout mice. Speciﬁcally, we assembled and
analyzed murine-speciﬁc biochemical network reconstructions
based on global (microarray-derived transcriptomic) renal gene
expression proﬁles in mURAT1 knockout and wild-type mice. Gene
expression data were used as weighting constraints on network
reactions, and the metabolite ﬂux-spans, which may be considered
to be measures of reaction functionality, were calculated for the
various reactions as previously described ([18,19]; please also see
Methods). Of the 3400 reactions in the genome scale metabolic
network, iMM1415 (please see Methods), 448 (13.18%) manifested
some degree of alteration in the knockout compared to wild-type
reconstructions (Supplementary Table 3). Among these, 102 had
ﬂux-spans increased by greater than two fold in the knockout
relative to the wild-type (Table 1), and 12 had ﬂux-spans de-
creased by greater than two fold (Table 2).
The proportions of these increased and decreased reactions in
the various metabolic subsystems of the reconstructions were
then determined (Fig. 3). (As an example, the chondroitin sulfate
metabolism subsystem comprises 44 reactions, the ﬂux-spans of
38 of which were increased by greater than two fold in the
knockout compared to the wild-type, corresponding to a
Fig. 2. Gene ontology functional annotation enrichment among genes differentially expressed or variable in the mURAT1 knockout. The enrichment of gene ontology (GO)
functional annotation terms among genes that are differentially expressed (panel A) or differentially variable (panel B) in the mURAT1 knockout compared with wild-type
mice was determined using AmiGO. GO terms are depicted in boxes shaded according to the statistical signiﬁcance of their enrichment and p values o105 are indicated.
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signiﬁcant increases in the mURAT1 knockout in metabolic func-
tions related to glycosaminoglycan metabolism (aminosugar me-
tabolism and chondroitin and keratan sulfate degradation), me-
thionine metabolism, and lysosomal and extracellular transport
(as indicated by a signiﬁcant proportion of the reactions in these
reconstructed sub-systems manifesting two fold or greater in-
crease in ﬂux-span in the knockout relative to wild-type; Table 1
and Fig. 3A). Conversely, the metabolic reconstructions featured
signiﬁcant decreases in functions related to coenzyme A bio-
synthesis (Table 2 and Fig. 3B).
Since mURAT1 is an extracellular membrane transporter, we
also examined all extracellular transport reactions altered to any
degree in the knockout reconstructions (and not just those having
greater than two fold ﬂux-span increases or decreases). There
were 46 extracellular transport reactions, corresponding to 40
transported metabolites, having ﬂux-span increases in the mUR-
AT1 knockout relative to wild-type reconstructions (Table 3), and
3 reactions, corresponding to 3 metabolites, having ﬂux-span de-
creases (Table 4). About a third of the compounds overall comprise
small organic anions of the kind that typically (although not ex-
clusively [18,19,22,23]) comprise substrates and inhibitors of the
multispeciﬁc OATs (Tables 3 and 4). Alterations in thereconstructions of transport of the remaining compounds might
reﬂect downstream consequences of the loss of URAT1.
In vitro data on the interactions of endogenous substrates with
URAT1 provide experimental support for these analyses. Four of
the compounds manifesting altered transport in the reconstruc-
tions have been demonstrated to interact with URAT1 in vitro;
these comprise urate as well as 2-oxoglutarate (α-ketoglutarate),
acetoacetate, and lactate [13]. Another two – pyruvate and pro-
gesterone – are known to interact with other members of the
organic anion transporter (OAT) family of which URAT1 is a
member [13,14,23]. Notably, nearly half (four of ten) of the URAT1-
interacting compounds of endogenous origin that were listed in a
comprehensive review [13] manifested altered transport in the
knockout reconstructions (Table 5), supporting the validity of our
analyses.4. Discussion
Multiple lines of evidence indicate an important role for URAT1
in the renal reabsorption of urate; in particular loss of function
URAT1 mutations have been repeatedly associated with decreased
urate reabsorption, resulting in hypouricemia, exercise-induced
Table 1
Reactions having greater than two fold-increased ﬂux-span in the mURAT1 knockout relative to wild-type reconstructions. Reactions are sorted by metabolic sub-
system and then by ﬂux-span ratio. The key to the abbreviations for reactions and formulae is available at the Biochemically, Genetically and Genomically structured
genome-scale metabolic network reconstructions database (BiGG; http://bigg.ucsd.edu/bigg/; accessed February 11th, 2015). KO, mURAT1 knockout; WT, wild-type.
Reaction Subsystem Formula WT Flux-span KO Flux-span Ratio (KO/
WT)
CMPSAS Aminosugar Metabolism acnam(c)þctp(c) -4 cmpacna(c)þppi(c) 0.00 2.00 Inf
CMPSASn Aminosugar Metabolism acnam(n)þctp(n) -4 cmpacna(n)þppi(n) 0.00 2.00 Inf
ACGALK Aminosugar Metabolism acgal(c)þatp(c) -4 acgal1p(c)þadp(c)þh(c) 0.00 6.50 Inf
ACGALK2 Aminosugar Metabolism acgal(c)þ itp(c) -4 acgal1p(c)þh(c)þ idp(c) 0.00 6.50 Inf
UAGALDP Aminosugar Metabolism acgal1p(c)þh(c)þutp(c) -4 ppi(c)þudpacgal(c) 0.00 6.50 Inf
NACHEX5ly Chondroitin sulfate degradation cs_c_deg4(l)þh2o(l) -4 acgal(l)þcs_c_deg5(l) 0.00 1.00 Inf
CSAPASEly Chondroitin sulfate degradation cspg_a(l)þh2o(l) -4 Ser-Gly/Ala-X-Gly(l)þcs_a(l) 0.00 1.00 Inf
CSCPASEly Chondroitin sulfate degradation cspg_c(l)þh2o(l) -4 Ser-Gly/Ala-X-Gly(l)þcs_c(l) 0.00 1.00 Inf
CSDPASEly Chondroitin sulfate degradation cspg_d(l)þh2o(l) -4 Ser-Gly/Ala-X-Gly(l)þcs_d(l) 0.00 1.00 Inf
CSEPASEly Chondroitin sulfate degradation cspg_e(l)þh2o(l) -4 Ser-Gly/Ala-X-Gly(l)þcs_e(l) 0.00 1.00 Inf
GLCAASE4ly Chondroitin sulfate degradation cs_a_deg2(l)þh2o(l) -4 cs_a_deg3(l)þglcur(l) 0.00 1.00 Inf
GLCAASE5ly Chondroitin sulfate degradation cs_c_deg2(l)þh2o(l) -4 cs_c_deg3(l)þglcur(l) 0.00 1.00 Inf
GLCAASE6ly Chondroitin sulfate degradation cs_d_deg3(l)þh2o(l) -4 cs_d_deg4(l)þglcur(l) 0.00 1.00 Inf
GLCAASE7ly Chondroitin sulfate degradation cs_e_deg3(l)þh2o(l) -4 cs_e_deg4(l)þglcur(l) 0.00 1.00 Inf
LINKDEG2ly Chondroitin sulfate degradation cs_a_deg5(l)þ4 h2o(l) -4 2 gal(l)þglcur(l)þh(l)þso4
(l)þxyl-D(l)
0.00 1.00 Inf
LINKDEG4ly Chondroitin sulfate degradation cs_e_deg7(l)þ5 h2o(l) -4 2 gal(l)þglcur(l)þ2 h(l)þ2
so4(l)þxyl-D(l)
0.00 1.00 Inf
NACHEX1ly Chondroitin sulfate degradation cs_a_deg1(l)þh2o(l) -4 acgal(l)þcs_a_deg2(l) 0.00 1.00 Inf
NACHEX2ly Chondroitin sulfate degradation cs_a_deg4(l)þh2o(l) -4 acgal(l)þcs_a_deg5(l) 0.00 1.00 Inf
NACHEX4ly Chondroitin sulfate degradation cs_c_deg1(l)þh2o(l) -4 acgal(l)þcs_c_deg2(l) 0.00 1.00 Inf
NACHEX6ly Chondroitin sulfate degradation cs_d_deg1(l)þh2o(l) -4 acgal(l)þcs_d_deg2(l) 0.00 1.00 Inf
NACHEX7ly Chondroitin sulfate degradation cs_d_deg5(l)þh2o(l) -4 acgal(l)þcs_d_deg6(l) 0.00 1.00 Inf
NACHEX8ly Chondroitin sulfate degradation cs_e_deg2(l)þh2o(l) -4 acgal(l)þcs_e_deg3(l) 0.00 1.00 Inf
NACHEX9ly Chondroitin sulfate degradation cs_e_deg6(l)þh2o(l) -4 acgal(l)þcs_e_deg7(l) 0.00 1.00 Inf
NACHEXA1ly Chondroitin sulfate degradation cs_a(l)þ2 h2o(l) -4 acgal(l)þcs_a_deg2(l)þh(l)þso4(l) 0.00 1.00 Inf
NACHEXA3ly Chondroitin sulfate degradation cs_c(l)þ2 h2o(l) -4 acgal(l)þcs_c_deg2(l)þh(l)þso4(l) 0.00 1.00 Inf
NACHEXA4ly Chondroitin sulfate degradation cs_c_deg3(l)þ2 h2o(l) -4 acgal(l)þcs_c_deg5(l)þh(l)þ
so4(l)
0.00 1.00 Inf
NACHEXA5ly Chondroitin sulfate degradation cs_d(l)þ2 h2o(l) -4 acgal(l)þcs_d_deg2(l)þh(l)þso4(l) 0.00 1.00 Inf
NACHEXA6ly Chondroitin sulfate degradation cs_d_deg4(l)þ2 h2o(l) -4 acgal(l)þcs_d_deg6(l)þh(l)þ
so4(l)
0.00 1.00 Inf
NACHEXA7ly Chondroitin sulfate degradation cs_e(l)þ3 h2o(l) -4 acgal(l)þcs_e_deg3(l)þ2 h(l)þ2
so4(l)
0.00 1.00 Inf
NACHEXA8ly Chondroitin sulfate degradation cs_e_deg4(l)þ3 h2o(l) -4 acgal(l)þcs_e_deg7(l)þ2 h
(l)þ2 so4(l)
0.00 1.00 Inf
S2TASE4ly Chondroitin sulfate degradation cs_d_deg2(l)þh2o(l) -4 cs_d_deg3(l)þh(l)þso4(l) 0.00 1.00 Inf
S2TASE5ly Chondroitin sulfate degradation cs_d_deg6(l)þh2o(l) -4 cs_c_deg5(l)þh(l)þso4(l) 0.00 1.00 Inf
S4TASE1ly Chondroitin sulfate degradation cs_a(l)þh2o(l) o¼4 cs_a_deg1(l)þh(l)þso4(l) 0.00 1.00 Inf
S4TASE2ly Chondroitin sulfate degradation cs_a_deg3(l)þh2o(l) o¼4 cs_a_deg4(l)þh(l)þso4(l) 0.00 1.00 Inf
S4TASE4ly Chondroitin sulfate degradation cs_e(l)þh2o(l) o¼4 cs_e_deg1(l)þh(l)þso4(l) 0.00 1.00 Inf
S4TASE5ly Chondroitin sulfate degradation cs_e_deg4(l)þh2o(l) o¼4 cs_e_deg5(l)þh(l)þso4(l) 0.00 1.00 Inf
S6TASE4ly Chondroitin sulfate degradation cs_c(l)þh2o(l) o¼4 cs_c_deg1(l)þh(l)þso4(l) 0.00 1.00 Inf
S6TASE5ly Chondroitin sulfate degradation cs_c_deg3(l)þh2o(l) o¼4 cs_c_deg4(l)þh(l)þso4(l) 0.00 1.00 Inf
S6TASE6ly Chondroitin sulfate degradation cs_d(l)þh2o(l) o¼4 cs_d_deg1(l)þh(l)þso4(l) 0.00 1.00 Inf
S6TASE7ly Chondroitin sulfate degradation cs_d_deg4(l)þh2o(l) o¼4 cs_d_deg5(l)þh(l)þso4(l) 0.00 1.00 Inf
S6TASE8ly Chondroitin sulfate degradation cs_e_deg1(l)þh2o(l) o¼4 cs_e_deg2(l)þh(l)þso4(l) 0.00 1.00 Inf
S6TASE9ly Chondroitin sulfate degradation cs_e_deg5(l)þh2o(l) o¼4 cs_e_deg6(l)þh(l)þso4(l) 0.00 1.00 Inf
LINKDEG3ly Chondroitin sulfate degradation cs_c_deg5(l)þ4 h2o(l) -4 2 gal(l)þglcur(l)þh(l)þso4
(l)þxyl-D(l)
0.00 2.00 Inf
MTHFCm Folate Metabolism h2o(m)þmethf(m) o¼4 10fthf(m)þh(m) 8.00 414.75 51.84
MTHFR3 Folate Metabolism 2 h(c)þmlthf(c)þnadph(c) -4 5mthf(c)þnadp(c) 7.00 417.73 59.68
MTHFC Folate Metabolism h2o(c)þmethf(c) o¼4 10fthf(c)þh(c) 83.00 450.59 5.43
CHOLK Glycerophospholipid Metabolism atp(c)þchol(c) -4 adp(c)þcholp(c)þh(c) 412.86 1000.00 2.42
ETHAK Glycerophospholipid Metabolism atp(c)þetha(c) -4 adp(c)þethamp(c)þh(c) 412.86 1000.00 2.42
GNMT Glycine, Serine, and Threonine
Metabolism
amet(c)þgly(c) -4 ahcys(c)þh(c)þsarcs(c) 4.00 412.86 103.22
GALASE16ly Keratan sulfate degradation 2 h2o(l)þksii_core2_deg2(l) -4 2 gal(l)þksii_cor-
e2_deg3(l)
0.00 1.00 Inf
GALASE20ly Keratan sulfate degradation 2 h2o(l)þksii_core4_deg2(l) -4 2 gal(l)þksii_cor-
e4_deg3(l)
0.00 1.00 Inf
NACHEX23ly Keratan sulfate degradation h2o(l)þksii_core2_deg4(l) -4 acgam(l)þksii_cor-
e2_deg5(l)
0.00 1.00 Inf
NACHEX26ly Keratan sulfate degradation 2 h2o(l)þksii_core4_deg4(l) -4 2 acgam(l)þksii_cor-
e2_deg5(l)
0.00 1.00 Inf
NACHEXA20ly Keratan sulfate degradation 2 h2o(l)þksii_core2_deg3(l) -4 acgam(l)þh(l)þksii_-
core2_deg5(l)þso4(l)
0.00 1.00 Inf
NACHEXA22ly Keratan sulfate degradation 3 h2o(l)þksii_core4_deg3(l) -4 2 acgam(l)þh(l)þksii_-
core2_deg5(l)þso4(l)
0.00 1.00 Inf
S6TASE22ly Keratan sulfate degradation h2o(l)þksii_core2_deg1(l) o¼4 h(l)þksii_core2_deg2
(l)þso4(l)
0.00 1.00 Inf
S6TASE23ly Keratan sulfate degradation h2o(l)þksii_core2_deg3(l) o¼4 h(l)þksii_core2_deg4 0.00 1.00 Inf
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Table 1 (continued )
Reaction Subsystem Formula WT Flux-span KO Flux-span Ratio (KO/
WT)
(l)þso4(l)
S6TASE25ly Keratan sulfate degradation h2o(l)þksii_core4_deg1(l) o¼4 h(l)þksii_core4_deg2
(l)þso4(l)
0.00 1.00 Inf
S6TASE26ly Keratan sulfate degradation h2o(l)þksii_core4_deg3(l) o¼4 h(l)þksii_core4_deg4
(l)þso4(l)
0.00 1.00 Inf
SIAASE3ly Keratan sulfate degradation h2o(l)þksii_core2(l) -4 acnam(l)þksii_core2_deg1(l) 0.00 1.00 Inf
SIAASE4ly Keratan sulfate degradation h2o(l)þksii_core4(l) -4 acnam(l)þksii_core4_deg1(l) 0.00 1.00 Inf
GALASE17ly Keratan sulfate degradation h2o(l)þksii_core2_deg5(l) -4 gal(l)þksii_core2_deg6(l) 0.00 2.00 Inf
GALASE18ly Keratan sulfate degradation h2o(l)þksii_core2_deg8(l) -4 gal(l)þksii_core2_deg9(l) 0.00 2.00 Inf
GALASE19ly Keratan sulfate degradation f1a(l)þh2o(l) -4 core6(l)þgal(l) 0.00 2.00 Inf
NACHEX24ly Keratan sulfate degradation h2o(l)þksii_core2_deg7(l) -4 acgam(l)þksii_cor-
e2_deg8(l)
0.00 2.00 Inf
NACHEX25ly Keratan sulfate degradation h2o(l)þksii_core2_deg9(l) -4 acgam(l)þ f1a(l) 0.00 2.00 Inf
NACHEXA21ly Keratan sulfate degradation 2 h2o(l)þksii_core2_deg6(l) -4 acgam(l)þh(l)þksii_-
core2_deg8(l)þso4(l)
0.00 2.00 Inf
NAGA2ly Keratan sulfate degradation Tn_antigen(l)þh(l)þudp(l) -4 Ser/Thr(l)þudpacgal(l) 0.00 2.00 Inf
NAGLCAly Keratan sulfate degradation core6(l)þh2o(l) -4 Tn_antigen(l)þacgam(l) 0.00 2.00 Inf
S6TASE24ly Keratan sulfate degradation h2o(l)þksii_core2_deg6(l) o¼4 h(l)þksii_core2_deg7
(l)þso4(l)
0.00 2.00 Inf
METAT Methionine Metabolism atp(c)þh2o(c)þmet-L(c) -4 amet(c)þpi(c)þppi(c) 67.50 413.06 6.12
AHC Methionine Metabolism ahcys(c)þh2o(c) o¼4 adn(c)þhcys-L(c) 4.00 413.06 103.27
PUNP1 Nucleotides adn(c)þpi(c) o¼4 ade(c)þr1p(c) 312.00 684.67 2.19
6HTSTSTERONEtr Transport, Endoplasmic Reticular 6htststerone(c) o¼4 6htststerone(r) 0.00 1.00 Inf
6HTSTSTERONEte Transport, Extracellular 6htststerone(c) o¼4 6htststerone(e) 0.00 1.00 Inf
AFLATOXINte Transport, Extracellular aﬂatoxin(e) o¼4 aﬂatoxin(c) 0.00 1.00 Inf
EAFLATOXINte Transport, Extracellular eaﬂatoxin(e) o¼4 eaﬂatoxin(c) 0.00 1.00 Inf
XYLt Transport, Extracellular xyl-D(e) o¼4 xyl-D(c) 0.00 3.25 Inf
CAATPS Transport, Extracellular atp(c)þ2 ca2(c)þh2o(c) -4 adp(c)þpi(c)þ2 ca2(e)þh
(e)
500.00 1000.00 2.00
CAt7r Transport, Extracellular ca2(c)þ3 na1(e) o¼4 3 na1(c)þca2(e) 1000.00 2000.00 2.00
NRPPHRtu Transport, Extracellular nrpphr(e) o¼4 nrpphr(c) 1000.00 2000.00 2.00
CMPACNAtg Transport, Golgi Apparatus cmpacna(c)þcmp(g) o¼4 cmp(c)þcmpacna(g) 0.00 2.00 Inf
CSPG_Atly Transport, Lysosomal cspg_a(e) -4 cspg_a(l) 0.00 1.00 Inf
CSPG_Ctly Transport, Lysosomal cspg_c(e) -4 cspg_c(l) 0.00 1.00 Inf
CSPG_Dtly Transport, Lysosomal cspg_d(e) -4 cspg_d(l) 0.00 1.00 Inf
CSPG_Etly Transport, Lysosomal cspg_e(e) -4 cspg_e(l) 0.00 1.00 Inf
KSII_CORE2tly Transport, Lysosomal ksii_core2(e) -4 ksii_core2(l) 0.00 1.00 Inf
KSII_CORE4tly Transport, Lysosomal ksii_core4(e) -4 ksii_core4(l) 0.00 1.00 Inf
UDPACGALtl Transport, Lysosomal udpacgal(c) o¼4 udpacgal(l) 0.00 2.00 Inf
UDPtl Transport, Lysosomal udp(c) o¼4 udp(l) 0.00 2.00 Inf
XYLtly Transport, Lysosomal xyl-D(l) -4 xyl-D(c) 0.00 3.25 Inf
ACGALtly Transport, Lysosomal acgal(l) -4 acgal(c) 0.00 6.50 Inf
GLCURtly Transport, Lysosomal glcur(c)þh(c) o¼4 glcur(l)þh(l) 2.00 8.50 4.25
SO4tl Transport, Lysosomal so4(l) o¼4 so4(c) 6.00 15.33 2.56
GALtly Transport, Lysosomal gal(l) -4 gal(c) 4.00 19.33 4.83
SARCStm Transport, Mitochondrial sarcs(c) -4 sarcs(m) 5.00 413.77 82.75
GLYtm Transport, Mitochondrial gly(c) o¼4 gly(m) 9.00 415.17 46.13
10FTHFtm Transport, Mitochondrial 10fthf(c) o¼4 10fthf(m) 324.50 666.67 2.05
ACNAMtn Transport, Nuclear acnam(c) -4 acnam(n) 0.00 2.00 Inf
CMPACNAtn Transport, Nuclear cmpacna(n) -4 cmpacna(c) 0.00 2.00 Inf
CTPtn Transport, Nuclear ctp(c) o¼4 ctp(n) 0.00 2.00 Inf
SARDHm Urea cycle/amino group metabolism fad(m)þsarcs(m)þthf(m) -4 fadh2(m)þgly(m)þmlthf
(m)
8.00 414.75 51.84
Table 2
Reactions having greater than two fold-decreased ﬂux-span in the mURAT1 knockout relative to wild-type reconstructions. Reactions are sorted by metabolic sub-
system and then by ﬂux-span ratio. The key to the abbreviations for reactions and formulae is available at the Biochemically, Genetically and Genomically structured
genome-scale metabolic network reconstructions database (BiGG; http://bigg.ucsd.edu/bigg/; accessed February 11th, 2015). KO, mURAT1 knockout; WT, wild-type.
Reaction Subsystem Formula WT Flux-span KO Flux-span Ratio (KO/WT)
DPCOAK CoA Biosynthesis atp(c)þdpcoa(c) -4 adp(c)þcoa(c)þh(c) 1.00 0.00 0.00
PNTK CoA Biosynthesis atp(c)þpnto-R(c) -4 4ppan(c)þadp(c)þh(c) 1.00 0.00 0.00
PPCDC CoA Biosynthesis 4ppcys(c)þh(c) -4 co2(c)þpan4p(c) 1.00 0.00 0.00
PPNCL3 CoA Biosynthesis 4ppan(c)þatp(c)þcys-L(c) -4 4ppcys(c)þamp(c)þh(c)þppi(c) 1.00 0.00 0.00
HSD3B11 Steroid Metabolism nad(c)þprgnlone(c) -4 h(c)þnadh(c)þprgstrn(c) 1.00 0.00 0.00
AKR1C1 Steroid Metabolism h(c)þnadph(c)þprgstrn(c) -4 aprgstrn(c)þnadp(c) 2.00 1.00 0.50
4MPTNLte Transport, Extracellular 4mptnl(c) o¼4 4mptnl(e) 1.00 0.00 0.00
APRGSTRNte Transport, Extracellular aprgstrn(e) o¼4 aprgstrn(c) 2.00 1.00 0.50
PRGSTRNt Transport, Extracellular prgstrn(e) o¼4 prgstrn(c) 2.00 1.00 0.50
4MPTNLtm Transport, Mitochondrial 4mptnl(c) o¼4 4mptnl(m) 1.00 0.00 0.00
PRGNLONEtm Transport, Mitochondrial prgnlone(c) o¼4 prgnlone(m) 1.00 0.00 0.00
3HLYTCL Tyrosine metabolism 34dhphe(c)þh(c) -4 co2(c)þdopa(c) 1.00 0.00 0.00
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Fig. 3. Metabolic sub-systems containing reactions with two-fold or greater change in ﬂux-span in mURAT1 knockout reconstructions. Proportions of the indicated me-
tabolic sub-systems comprising reactions having ﬂux-spans increased (panel A) or decreased (panel B) by two-fold or greater in the mURAT1 knockout relative to wild-type
reconstructions are depicted. The actual number of reactions increased or decreased by two-fold or greater than is indicated above each column. Error bars denote the
standard error of the proportion; black columns, po0.001; dark gray columns, po0.01; light gray columns, po0.05; open columns, NS.
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dothelial dysfunction [24–28]. However, as noted in the In-
troduction, recent data indicates that other transporters also make
signiﬁcant contributions to urate reabsorption [11,17,29,30] and
that URAT1 has other substrates besides urate (Table 5). These
ﬁndings suggest additional functions for URAT1 beyond urate
transport. Consistent with this notion, the metabolic reconstruc-
tions presented here, based on computational deﬁnition of the
biochemical pathways consistent with the mURAT1 knockout
transcriptomic data, suggest multiple metabolic alterations in the
mURAT1 knockout mouse distinct from urate handling. As dis-
cussed further below, the set of metabolic reactions associated
with mURAT1 manifests some commonalities with those pre-
viously reported for the related transporters, OAT1 and OAT3
[18,19]. It is also notable that many more reactions had increased
functionality in the mURAT1 knockout mouse reconstructions
than had decreased functionality, possibly indicating that loss of
mURAT1 induces a heightened state of metabolic compensation.
This is in contrast to the OAT1 and OAT3 knockout reconstructions
which had more reactions with decreased than increased func-
tionality [18,19].
Metabolites having altered extracellular membrane transport
in the mURAT1 knockout mouse reconstructions included several
that are plausible URAT1 substrates on the basis of their previously
demonstrated in vitro interactions with this transporter and/or
other OAT family members (Tables 3 and 4) – indeed, four of the
ten known URAT1-interacting substrates of endogenous origin
were represented among these molecules (Table 5). Overall, these
ﬁndings suggest the potential involvement of URAT1 in bioener-
getic pathways (via transport of acetoacetate, α-ketoglutarate,
lactate, and pyruvate), nucleotide metabolism (via transport of
urate), and steroid signaling or metabolism (via transport of or
interaction with progesterone). With regard to the latter process,progestgerone and two other intermediates in steroid metabolism
((20 S)-20-hydroxypregn-4-en-3-one and 4-methylpentanal)
comprised the three compounds manifesting decreased transport
in the knockout reconstructions (each by two fold or greater).
Alterations in the reconstructions of transport of non-OAT
substrates and of the non-transport metabolic subsystems pre-
sumably reﬂect possible secondary or downstream effects of
mURAT1 loss, including those due to genomic regulatory feedback.
These changes involved multiple cellular processes and biochem-
ical pathways taking place in the cytosol, lysosomes, and mi-
tochondria. Prominent among them were increases in functional-
ities relating to lysosomal turnover of glycosaminoglycans (poly-
mers of aminosugars that constitute the glycan component of
glycosylated proteins [31,32]): A signiﬁcant proportion of the re-
actions belonging to the subsystems of aminosugar metabolism
and degradation of the glycosaminoglycans, chondroitin and ker-
atan sulfate, had ﬂux-span increases greater than two fold in the
mURAT1 knockout compared with wild-type reconstructions
(Fig. 3A). Moreover, in the lysosomal transport sub-system, which
also had a signiﬁcant proportion of increased reactions in the
knockout reconstructions, all of the affected reactions involved
transport of glycosaminoglycans or aminosugars (Fig. 3A and Ta-
ble 1). Notably, altered glycosaminoglycan metabolism was also a
feature of our gene expression-constrained reconstructions of
metabolism in the OAT1 and OAT3 knockouts [18,19].
Glycosaminoglycans are not only important elements of the
extracellular matrix but are also critical to cell-cell communication
mediated by integral membrane proteins and soluble factors [32].
For example, emerging evidence indicates that extracellular matrix
glycosaminoglycans may modulate growth factor signaling during
branching morphogenesis in the kidney (reviewed in [33]). Thus,
our ﬁndings suggesting altered metabolism of these molecules in
mURAT1 knockout mice raise the possibility of a role for mURAT1
Table 3
Metabolites associated with extracellular transport reactions having increased ﬂux-span in the mURAT1 knockout reconstructions. Metabolites are sorted by whether or not they are known to interact with URAT1 or other
members of the organic anion transporter (OAT) family, and then by the ﬂux-span ratios of their associated transport reactions. The key to the abbreviations for reactions and formulae is available at the Biochemically, Genetically
and Genomically structured genome-scale metabolic network reconstructions database (BiGG; http://bigg.ucsd.edu/bigg/; accessed February 11th, 2015). KO, mURAT1 knockout; WT, wild-type; x, OAT-interacting compound; y,
URAT1-interacting compound. Transporter-metabolite interactions were derived from a comprehensive review [13].
Metabolite Name OAT-interacting
compound
URAT1-interacting
compound
Transport Reaction Formula WT Flux-span KO Flux-span Flux-span Ratio
(KO/WT)
Urate x y URATEt urate(c) -4 urate(e) 39.333 42.389 1.078
Acetoacetate x y ACACt2 acac(e)þh(e) o¼4 acac(c)þh(c) 288.027 308.913 1.073
Lactate x y D-LACt2 h(e)þ lac-D(e) o¼4 h(c)þ lac-D(c) 290.771 311.816 1.072
2-Oxoglutarate x y AKGt4_3 akg(e)þ3 na1(e) o¼4 akg(c)þ3 na1(c) 149.401 159.910 1.070
Pyruvate x PYRt2r h(e)þpyr(e) o¼4 h(c)þpyr(c) 293.212 313.866 1.070
6 beta hydroxy testosterone 6HTSTSTERONEte 6htststerone(c) o¼4 6htststerone(e) 0.000 1.000 Inf
aﬂatoxin B1 AFLATOXINte aﬂatoxin(e) o¼4 aﬂatoxin(c) 0.000 1.000 Inf
aﬂatoxin B1 exo-8,9-epoxide EAFLATOXINte eaﬂatoxin(e) o¼4 eaﬂatoxin(c) 0.000 1.000 Inf
D-Xylose XYLt xyl-D(e) o¼4 xyl-D(c) 0.000 3.250 Inf
Calcium CAATPS atp(c)þ2 ca2(c)þh2o(c) -4 adp(c)þpi(c)þ2 ca2
(e)þh(e)
500.000 1000.000 2.000
Calcium CAt7r ca2(c)þ3 na1(e) o¼4 3 na1(c)þca2(e) 1000.000 2000.000 2.000
Norepinephrine NRPPHRtu nrpphr(e) o¼4 nrpphr(c) 1000.000 2000.000 2.000
Dopamine DOPAtu dopa(e) o¼4 dopa(c) 1001.000 2000.000 1.998
Norepinephrine NRPPHRVESSEC 2 atp(c)þ2 h2o(c)þ3 nrpphr(c) -4 2 adp(c)þ2 h
(c)þ2 pi(c)þ3 nrpphr(e)
333.333 520.601 1.562
Dopamine DOPAVESSEC 2 atp(c)þ3 dopa(c)þ2 h2o(c) -4 2 adp(c)þ2 h(c)þ
2 pi(c)þ3 dopa(e)
333.667 520.601 1.560
Dehydroascorbate DHAAt1r dhdascb(e) o¼4 dhdascb(c) 101.833 125.500 1.232
L-Arabinitol ABTti abt(c) -4 abt(e) 102.167 125.833 1.232
Xylitol XYLTt xylt(e) o¼4 xylt(c) 102.167 125.833 1.232
D-Fructose FRUt4 fru(e)þna1(e) o¼4 fru(c)þna1(c) 101.000 123.778 1.226
Deoxyribose DRIBt drib(e) o¼4 drib(c) 124.000 151.333 1.220
Acetaldehyde ACALDt acald(e) o¼4 acald(c) 312.000 380.333 1.219
Deoxyuridine DURIt duri(e) o¼4 duri(c) 63.500 72.667 1.144
Uridine URIt uri(e) o¼4 uri(c) 63.500 72.667 1.144
Cytidine CYTDt cytd(e) o¼4 cytd(c) 42.333 48.444 1.144
Formate CLFORtex 2 for(c)þcl(e) -4 cl(c)þ2 for(e) 33.750 38.333 1.136
Glycerol GLYCt glyc(c) o¼4 glyc(e) 134.405 149.252 1.110
Methylglyoxal MTHGXLt mthgxl(c) -4 mthgxl(e) 500.000 553.431 1.107
Guanosine GSNt gsn(e) o¼4 gsn(c) 33.714 36.333 1.078
Deoxyguanosine DGSNt dgsn(e) o¼4 dgsn(c) 33.714 36.333 1.078
Hexadecenoate (n-C16:1); Palmitoleic
acid
HDCEAtr hdcea(e) o¼4 hdcea(c) 92.023 98.585 1.071
linoelaidic acid (all trans C18:2) LNELDCt lneldc(e) o¼4 lneldc(c) 79.926 85.613 1.071
elaidic acid ELAIDt elaid(e) o¼4 elaid(c) 80.997 86.748 1.071
vaccenic acid VACCt vacc(e) o¼4 vacc(c) 80.997 86.748 1.071
acetone ACETONEt2 acetone(e)þh(e) o¼4 acetone(c)þh(c) 463.750 494.880 1.067
fatty acid retinol RETFAt retfa(c) -4 retfa(e) 309.429 330.167 1.067
Retinol RETt retinol(e) -4 retinol(c) 306.658 327.167 1.067
diacylglycerol DAGt dag_hs(e) o¼4 dag_hs(c) 348.108 371.373 1.067
(R)-3-Hydroxybutanoate BHBt bhb(e)þh(e) o¼4 bhb(c)þh(c) 285.288 304.282 1.067
R total 2 position RTOTAL2t Rtotal2(e) o¼4 Rtotal2(c) 393.916 420.137 1.067
triacylglycerol TAGt tag_hs(e) o¼4 tag_hs(c) 308.684 329.194 1.066
R total 3 position RTOTAL3t Rtotal3(e) o¼4 Rtotal3(c) 396.916 423.137 1.066
monoacylglycerol 3 MAGt mag_hs(e) o¼4 mag_hs(c) 78.635 83.736 1.065
R total RTOTALt Rtotal(e) o¼4 Rtotal(c) 91.250 96.970 1.063
omega hydroxy tetradecanoate (n-
C14:0)
WHTTDCAte whttdca(e) o¼4 whttdca(c) 92.762 95.786 1.033
omega hydroxy tetradecanoate (n-
C14:0)
WHHDCAte whhdca(e) o¼4 whhdca(c) 83.381 85.236 1.022
hydrogen peroxide H2O2t h2o2(e) o¼4 h2o2(c) 1158.530 1159.224 1.001
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Table 4
Metabolites associated with extracellular transport reactions having decreased ﬂux-span in the mURAT1 knockout reconstructions. Metabolites are sorted by whether or not
they are known to interact with URAT1 or other members of the organic anion transporter (OAT) family, and then by the ﬂux-span ratios of their associated transport
reactions. The key to the abbreviations for reactions and formulae is available at the Biochemically, Genetically and Genomically structured genome-scale metabolic network
reconstructions database (BiGG; http://bigg.ucsd.edu/bigg/; accessed February 11th, 2015). KO, mURAT1 knockout; WT, wild-type; x, OAT-interacting compound. Trans-
porter-metabolite interactions were derived from a comprehensive review [13].
Metabolite Name OAT-interacting
compound
URAT1-interacting
compound
Transport Reaction Transport Reaction
Formula
WT Flux-
span
KO Flux-
span
Flux-span Ratio
(KO/WT)
progesterone x PRGSTRNt prgstrn(e) o¼4
prgstrn(c)
2.000 1.000 0.500
4-methylpentanal 4MPTNLte 4mptnl(c) o¼4
4mptnl(e)
1.000 0.000 0.000
(20 S)-20-hydroxypregn-4-en-
3-one
APRGSTRNte aprgstrn(e) o¼4
aprgstrn(c)
2.000 1.000 0.500
Table 5
Endogenous URAT1-interacting compounds from a comprehensive review [13].
Shaded rows indicate compounds manifesting altered transport in the mURAT1
knockout reconstructions. h, human; m, mouse; r, rat.
URAT1-interacting compound URAT1 ortholog tested Expression System
Acetoacetate h X.laevis
Dehydroepiandrosterone sulfate m HEK293 cell line
Hydroxybutyrate h X.laevis
Ketoglutarate h X.laevis
Lactate h X.laevis
m X.laevis
Nicotinate h X.laevis
Orotate h X.laevis
Succinate h X.laevis
Urate h HEK293 cell line
X.laevis
m X.laevis
r Proteoliposome
β-hydroxybutyric acid h X.laevis
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gated by the lack of obvious developmental anomalies in the
knockouts [17]. Moreover, altered glycosylation is a virtually uni-
versal feature of malignancy [32] so that URAT1 involvement in
glycosaminoglycan metabolism may also have implications for
pathophysiological mechanisms in cancer. Notably, glycosami-
noglycans bind lipoproteins and may thereby modulate choles-
terol levels [32]. Thus involvement in glycosaminoglycan meta-
bolism may help explain the relationship between uric acid and
cardiovascular disease.
Methionine and associated one-carbon metabolism also mani-
fested increased functionality in the mURAT1 knockout re-
constructions (Fig. 3A and Table 1). Methionine is a precursor to
homocysteine, elevated plasma levels of which represent a cardi-
ovascular risk factor [34]. Notably in this regard, reactions invol-
ving the metabolism of folate, which is necessary for the recycling
of homocysteine to methionine and is thus cardio-protective, were
also increased in the knockout reconstructions, though not to a
statistically signiﬁcant degree (Fig. 3A and Table 1). As with gly-
cosaminoglycan metabolism, the possible involvement of URAT1
in methionine and folate metabolism may contribute to the links
between uric acid and cardiovascular disease.
Conversely, functions related to the biosynthesis of coenzyme
A, required in the Krebs cycle and for fatty acid metabolism, were
signiﬁcantly decreased in the mURAT1 knockout reconstructions
(Fig. 3B and Table 2), consistent with the role for mURAT1 in renal
cellular bioenergetics that was suggested by the alterations in the
reconstructions of transport of metabolic intermediates. Of note,
the URAT1-related transporters, OAT1 and OAT3, were also im-
plicated in cellular bioenergetics in our prior network analyses
[18,19]). The possible involvement of URAT1 in coenzyme A me-
tabolism could have implications for the variousneurodegenerative and metabolic disorders that involve coenzyme
A dysregulation [35–37].
Accumulating data indicate that OAT1 and OAT3, previously
primarily studied in terms of their role in mediating the renal
secretion of numerous important organic anionic pharmaceuticals
(e.g., non-steroidal anti-inﬂammatory drugs, β-lactam antibiotics,
loop and thiazide diuretics), in fact handle a diverse array of me-
tabolically and clinically signiﬁcant endogenous substrates (e.g.,
Krebs cycle intermediates, uremic toxins, enterobiome products,
cyclic nucleotides, prostaglandins, and steroid conjugates)
[13,14,38,39], suggesting their function in various physiological
processes. Indeed, mice null for OAT3 are relatively hypotensive,
indicating a role for this transporter in the regulation of blood
pressure [23]. Moreover, the expression of these and related
transporters in widely dispersed tissues (including liver, olfactory
mucosa, and choroid plexus of the brain, in addition to kidney)
and their transport of signaling molecules (as listed above) raise
the possibility that they participate in organism-wide commu-
nication networks (which has been termed the “remote sensing
and signaling hypothesis”) [38–40]. The metabolic reconstructions
presented here are in line with likewise physiological roles for
mURAT1.
In summary, in the context of a growing number of URAT1
substrates other than urate, the identiﬁcation of other clinically
important uric acid transporters (e.g., slc2a9, ABCG2), and the
presence of metabolomic changes in the mURAT1 knockout (al-
though the involved metabolites could not be identiﬁed), we have
used gene expression data from mURAT1 knockout mice to com-
putationally constrain pathway reconstructions, thereby allowing
global characterization of metabolic networks potentially asso-
ciated with mURAT1. While there is need for follow up physiolo-
gical studies analyzing the knockout mice under conditions of
perturbed as well as basal homoeostasis, our ﬁndings suggest that
mURAT1 has additional functions beyond urate reabsorption, in-
cluding in bioenergtic and biosynthetic metabolism; as detailed
above many of these functions overlap those of the closely related
transporters, OAT1 and OAT3. Moreover, since mURAT1 and hUR-
AT1 are at least as phylogenetically similar as most mouse-human
orthologous gene pairs (they manifest 81% sequence similarity and
74% identity at the amino acid level [1,2,15], slightly superior to
the mean 70.1% identity across all mouse-human orthologs [41]),
these additional functions may also occur in humans. While the
much higher levels of urate in humans than mice could result in
greater competitive inhibition by urate of these other URAT1
functions, such inhibition would not be expected to be complete.
Urate concentrations in human plasma generally fall in the range
200-500 uM, the midpoint of which, 350 mM, is approximately
equivalent to the apparent afﬁnity (Km) of urate for URAT1, which
was estimated to be 371 mM [1]. Thus, on average, circulating urate
might be expected to occupy about half of the available URAT1
S.A. Eraly et al. / Biochemistry and Biophysics Reports 3 (2015) 51–6160transporters, so that transport of any other substrates would be
reduced but not eliminated. Accordingly, our ﬁndings in URAT1
knockout mice could potentially have implications for human
physiology, including for our understanding of the relationship
between uric acid and the various metabolic disorders to which it
has been linked.Grants
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